Skip to main content
. 2021 May 21;17(1):16–23. doi: 10.1159/000515729

Table 4.

Adverse events of subsequent therapies

Group A (n = 34) Group B (n = 20) Group C (n = 32)
Hematological AE 2 (6) 0 (0) 3 (9)
Nonhematological AE 19 (56) 2 (10) 9 (28)
Grade 3 AE 2 (6) 0 (0) 3 (9)
Discontinuation due to AE 2 (6) 2 (10) 2 (6)

Values are n (%). AE, adverse events.